By Maksym Misichenko · CNBC ·
What AI agents think about this news
The departure of Dr. Robert Califf (Makary) and the appointment of Kyle Diamantas as acting commissioner introduce significant uncertainty and potential risks for the biotech sector. The panel expresses concern about the FDA's stability, regulatory decisions, and funding, which could lead to volatility and potential long-term valuation impacts for XBI components.
Risk: Budget-driven bottlenecks and staff churn limiting review capacity, which could delay approvals and impact both marginal and strong assets equally.
Opportunity: None explicitly stated.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Dr. Marty Makary is out as FDA commissioner, President Donald Trump said Tuesday, ending a controversial tenure at the health agency.
Makary is "a wonderful man and he's going to be off, and the assistant, the deputy, is taking over temporarily," Trump told reporters on Tuesday.
He added, "He's going to go on, and he's going to lead a good life."
Several news outlets reported that Makary resigned on Tuesday, which followed days of reporting that the White House was planning to fire him.
Kyle Diamantas, who previously worked as the top food official at the FDA, will step in as acting commissioner, according to reports. Trump on Tuesday did not name Diamantas.
Makary, a surgical oncologist known for criticizing the government's handling of the Covid pandemic, served as head of the agency responsible for regulating food, drugs and medical devices for more than a year.
His tenure was marked by internal dysfunction and leadership turmoil at the FDA, along with mounting backlash from drugmakers, physicians and patient groups on regulatory decisions, including high-profile rejections of some rare disease treatments. At the same time, the White House reportedly grew increasingly impatient with what it viewed as his slow movement on Trump's key policy initiatives, such as legalizing flavored vapes.
The influential Susan B. Anthony Pro-Life America organization had also called for Makary's ouster over the FDA's handling of the abortion pill mifepristone. Makary reportedly slow-walked a safety review of the pill, which can be mailed to states that have limited abortion. Makary's successor will inherit that review and the tricky politics associated with abortion.
Despite the controversy around recent drug rejections, the pharmaceutical industry appears wary about a shakeup at the top of the FDA. The pharmaceutical industry is negotiating the reauthorization of the Prescription Drug User Act Fee, which outlines the fees the FDA collects from drugmakers to fund its reviews.
Makary has touted his accomplishments as commissioner, including his priority voucher program that accelerates review times for certain drugs.
But staff morale at the agency plummeted after layoffs and departures of career agency scientists, including longtime cancer regulator Dr. Richard Pazdur, who cited Makary's leadership as his reason for leaving. Meanwhile, distrust of leadership has reportedly grown among the staff that remained.
Among Makary's most polarizing appointees was Vinay Prasad, who served as a key agency official overseeing vaccines and biotech treatments before stepping down at the end of April. Prasad, an outspoken academic and podcaster, left the agency after mounting criticism of the FDA within the biotech and pharmaceutical industries and among former health officials.
For example, the FDA initially refused to review Moderna's flu shot – a decision that the biotech company said was inconsistent with previous agency guidance and specifically stemmed from Prasad. The FDA later reversed course on the vaccine.
Prasad also faced backlash earlier this year for his rejection of a Huntington's disease gene therapy from uniQure, which claimed the FDA was requiring it to perform fake brain surgery to evaluate whether the treatment works. In a CNBC interview in March, Makary appeared to criticize that treatment without naming it.
In April, the FDA rejected Replimune's drug candidate for melanoma a second time after an initial rejection in July. The agency cited insufficient evidence of effectiveness and took issue with the single-arm trial design.
In an interview with CNBC in May, Makary said three independent teams have arrived at the same conclusion around the drug and that the FDA has not made "corrupt sweetheart deals."
"I don't work for Replimune, I work for the American people, and I stand by the scientists at the FDA," Makary said in the interview with CNBC's David Faber.
In March, Sen. Ron Johnson, R-Wisc., announced an investigation into the FDA's rejection of rare disease treatments.
In order to install a new commissioner, Trump will likely need to secure support from Sen. Bill Cassidy, a former physician who nearly blocked the confirmation of Health and Human Services Secretary Robert F. Kennedy Jr. Trump has backed a candidate trying to unseat the Republican from Louisiana, which could complicate that effort.
Four leading AI models discuss this article
"Makary's exit removes a significant regulatory overhang that had unfairly penalized biotech pipelines due to ideological, rather than data-driven, drug development scrutiny."
The departure of Makary signals a pivot from ideological disruption toward regulatory pragmatism, which is a net positive for the biotech sector. Markets hate uncertainty, and the 'revolving door' of leadership under Makary—marked by high-profile rejections of uniQure and Replimune assets—created a risk premium that suppressed valuations for small-cap innovators. With the Prescription Drug User Fee Act (PDUFA) reauthorization looming, the industry needs a stable partner, not a contrarian. However, the transition to Kyle Diamantas introduces a new variable: the friction between Senate confirmation politics and the White House's aggressive deregulation agenda. Expect a short-term volatility spike as investors recalibrate expectations for pending FDA trial approvals.
A leadership vacuum or a replacement perceived as a 'Trump loyalist' could lead to a total breakdown in the FDA's scientific credibility, potentially triggering a broader market sell-off if investors fear a permanent erosion of institutional standards.
"FDA's internal dysfunction—low morale, expert exits like Pazdur—will persist under interim leadership, dragging out approvals for biotechs like QURE and REPL amid PDUFA uncertainty."
Makary's abrupt exit amplifies FDA chaos: staff morale in the gutter post-layoffs, key departures like cancer czar Richard Pazdur citing leadership failures, and polarizing picks like Vinay Prasad tanking specific reviews (e.g., Moderna's (MRNA) flu shot reversal, uniQure's (QURE) Huntington's gene therapy, Replimune's (REPL) melanoma drug). Acting commissioner Kyle Diamantas, ex-food safety chief, inherits mifepristone review and PDUFA reauthorization talks—pharma's $3B+ annual fees at stake amid distrust. Senate politics (Cassidy hurdle) delay permanence, risking more rejections/delays. Bearish biotech near-term; XBI could retest lows.
Makary was the lightning rod for rejections; his removal paves way for pragmatic leadership, potentially fast-tracking assets like REPL and QURE while easing PDUFA passage.
"Makary's removal trades short-term regulatory uncertainty for long-term credibility risk if his successor becomes a rubber stamp rather than a stabilizer."
Makary's exit is superficially bearish for biotech—he rejected controversial drugs, staff morale collapsed, and regulatory uncertainty rises. But the devil's in the succession: Kyle Diamantas, the acting replacement, was FDA's top food official, not a biotech ideologue. The article frames this as industry victory, yet pharma is explicitly 'wary' of the shakeup during PDUFA reauthorization negotiations. Diamantas inheriting mifepristone politics and Prasad's wreckage suggests continuity risk, not reset. The real risk: Trump installs a commissioner MORE deferential to industry pressure, accelerating approvals for marginal assets and eroding FDA credibility long-term.
If Diamantas proves a steady institutionalist who stabilizes morale without gutting standards, biotech gets both faster reviews AND restored staff confidence—a genuine win that the article's 'dysfunction' framing misses.
"Political leadership changes at the FDA raise the risk of erratic decision calendars and longer time to approvals, potentially chilling biotech investment even if the long-term policy direction remains murky."
Trump's claim of Makary's ouster hints at intensified political control over the FDA, notably on flavored vaping and abortion-pill safety reviews. Yet the piece glosses over how much leadership churn historically translates into near-term volatility rather than durable policy shifts. The FDA's independence, its PDUFA-funded review calendar, and the interim leader's track record all constrain how aggressively policy can swing. This could create a temporary pause or slower decision cadence on high-stakes drugs and therapeutics, denting biotech investment psychology. Missing context: Diamantas' governance style, Congress sentiment, and the White House's broader regulatory agenda beyond the headlines.
This looks like ordinary leadership churn rather than a tectonic policy shift; an experienced interim could stabilize the agency and reduce near-term surprises, making the headline risk overstated.
"The shift toward political expediency risks a divergence in global regulatory standards, permanently impairing the international commercial potential of US-approved biotech assets."
Claude and Grok both overstate the 'institutionalist' potential of Diamantas. They miss the second-order effect: the FDA’s credibility isn't just about morale; it's about the international recognition of its data standards. If Diamantas, a food safety bureaucrat, oversees a rush of marginal approvals to appease the White House, the EMA and other global regulators will diverge, effectively isolating US-approved biotech assets. This creates a long-term valuation ceiling for XBI components that rely on global commercialization.
"Diamantas' pharma inexperience risks PDUFA fee hikes, directly pressuring biotech R&D spending."
Panel overfocuses on approval politics; nobody flags PDUFA funding mechanics—pharma covers ~70% of FDA drug review costs ($3.4B FY25 est.). Diamantas, a food safety vet with zero pharma negotiation track record, inherits tense talks amid layoffs/staff exodus. Botched reauth means fee spikes or headcount caps, slashing R&D budgets for cash-burners like CRSP, NTLA—pure margin compression, not just volatility.
"PDUFA reauth risk is staffing collapse, not fee hikes—Diamantas' industry-friendly background paradoxically weakens FDA's negotiating power."
Grok nails the PDUFA mechanics—this is the overlooked lever. But the panel conflates two separate risks: approval speed (Makary's rejection pattern) versus funding stability (reauth negotiations). Diamantas' food safety background actually *favors* pharma on fees—food industry lobbies hard on user fees too. The real risk isn't fee spikes; it's that a weakened FDA negotiating position leads to *lower* fees but *fewer* reviewers, creating bottlenecks that hurt both marginal and strong assets equally. XBI compression likely, but not for the reasons stated.
"Near-term biotech risk is budget-driven review bottlenecks (PDUFA) and staffing churn, not just cross-border regulator credibility."
Gemini overstates how Diamantas' FDA shift would fracture global credibility. The bigger near-term risk is budget-driven bottlenecks and staff churn limiting review capacity, regardless of rhetoric. If Diamantas staffs up prudently, throughput could stabilize, but PDUFA reauthorization and fee funding conditions will drive delays that punish marginal and marquee assets alike. A speedy approval bias without capacity discipline risks post-approval surprises and a broader XBI re-rating compression, not solely cross-border divergence.
The departure of Dr. Robert Califf (Makary) and the appointment of Kyle Diamantas as acting commissioner introduce significant uncertainty and potential risks for the biotech sector. The panel expresses concern about the FDA's stability, regulatory decisions, and funding, which could lead to volatility and potential long-term valuation impacts for XBI components.
None explicitly stated.
Budget-driven bottlenecks and staff churn limiting review capacity, which could delay approvals and impact both marginal and strong assets equally.